Technical Analysis for NITE - Capitol Series Trust The Nightview Fund NITE
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | 1.78% | |
| New 52 Week High | Strength | 1.78% | |
| Gapped Up | Strength | 1.78% | |
| Up 3 Days in a Row | Strength | 1.78% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 8 hours ago |
| New 52 Week High | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 8 hours ago |
| Rose Above Previous Day's High | 1 day ago |
Get this analysis on your stocks daily!
Capitol Series Trust The Nightview Fund NITE Description
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 2/3 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was incorporated in 2017 and is headquartered in London, the United Kingdom.
Classification
Keywords: Molecular Biology Gene Therapy Medical Genetics Retina Gene Delivery Retinal Diseases Retinitis Pigmentosa Choroideremia Stargardt Disease X Linked Retinitis Pigmentosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.28 |
| 52 Week Low | 24.86 |
| Average Volume | 8,523 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.47 | ||||
| Resistance 3 (R3) | 26.46 | 26.37 | 26.43 | ||
| Resistance 2 (R2) | 26.37 | 26.31 | 26.38 | 26.41 | |
| Resistance 1 (R1) | 26.29 | 26.27 | 26.33 | 26.30 | 26.40 |
| Pivot Point | 26.20 | 26.20 | 26.22 | 26.21 | 26.20 |
| Support 1 (S1) | 26.12 | 26.14 | 26.16 | 26.13 | 26.03 |
| Support 2 (S2) | 26.03 | 26.10 | 26.04 | 26.02 | |
| Support 3 (S3) | 25.95 | 26.03 | 26.00 | ||
| Support 4 (S4) | 25.96 |
